To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

Refractory Status Epilepticus Clinical Trial

Official title:

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05814523
• Other study ID #: 1042-SE-3004
• Status: Withdrawn
• Phase: Phase 3
• Start date: March 2024
• Est. completion date: August 2024

Study information

• Verified date: May 2024
• Source: Marinus Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, double-blind, randomized, placebo-controlled study that will evaluate the efficacy, safety, and tolerability of intravenous (IV) ganaxolone versus placebo co-administered with IV antiepileptic drug (AED) according to standard of care for the treatment of RSE. Approximately 70 participants will be randomized in a 1:1 ratio to receive ganaxolone IV solution or placebo IV solution along with standard of care (SOC) IV AED.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participant, participant's parent, guardian, or LAR must provide signed informed consent/assent, and once capable (per institution guidelines), there must be documentation of consent/assent by the participant demonstrating they are willing and aware of the investigational nature of the study and related procedures. Where allowed by law, where the participant lacks the capacity to make informed decisions regarding his/her medical treatment options, the treating clinician may follow their deferred consenting practices. The clinician will make the final decision based on the best interests of the participant.

2. Male or females 18 years of age and older at the time of the first dose of IP.

3. SE warranting imminent progression of treatment meeting the following criteria:

a) A diagnosis of SE, warranting imminent progression of treatment for seizure control, with or without prominent motor features based on clinical and EEG findings:

i. Diagnosis is established by:

• For SE with prominent motor features: Clinical and EEG seizure activity indicative of convulsive, myoclonic, or focal motor SE.

• For SE without prominent motor features (nonconvulsive SE): Appropriate clinical features and an EEG indicative of non-convulsive status epilepticus (NCSE).

ii. For any type of SE:

• At least 6 minutes of cumulative seizure activity over a 30-minute period within the hour before IP initiation, AND Seizure activity during the 30 minutes immediately prior to IP initiation.

4. Participants must have received a benzodiazepine and at least 1 of the following IV AEDs for treatment of the current episode of SE administered at an adequate dose and for a sufficient duration, in the judgement of the investigator, to demonstrate efficacy. The benzodiazepine and at least 1 of the IV AEDs must have been administered at a dose that would be expected to be effective for the termination of the current episode of SE.

• IV Fosphenytoin/phenytoin,

• IV Valproic acid,

• IV Levetiracetam,

• IV Lacosamide,

• IV Brivaracetam, or

• IV Phenobarbital.

5. Body mass index (BMI) < 40 or, if BMI is not able to be calculated at screening, participant is assessed by investigator as not morbidly obese.

Exclusion Criteria:

1. Life expectancy of less than 24 hours.

2. Anoxic brain injury or an uncorrected, rapidly reversable metabolic condition as the primary cause of SE (eg, hypoglycemia < 50 milligrams per deciliter [mg/dL] or hyperglycemia > 400 mg/dL).

3. Participants who have received high-dose IV anesthetics (eg, midazolam, propofol, thiopental, or pentobarbital) during the current episode of SE for more than 18 hours, or who continue to have clinical or electrographic evidence of persistent seizures while receiving high-dose IV anesthetics.

4. Clinical condition or advance directive that would NOT permit admission to the ICU or use of IV anesthesia.

5. Participants known or suspected to be pregnant

6. Participants with known allergy or sensitivity to progesterone or allopregnanolone medications/supplements

7. Receiving a concomitant IV product containing Captisol.

8. Known or suspected hepatic insufficiency or hepatic failure leading to impaired synthetic liver function.

9. Known or suspected stage 3B (moderate to severe; estimated glomerular filtration rate [eGFR] 44-30 milliliters per minute per 1.73-meter square [mL/min/1.73m^2]), stage 4 (severe; eGFR 29-15 mL/min/1.73m^2), or stage 5 (kidney failure; eGFR < 15 mL/min/1.73m^2 or dialysis) kidney disease.

10. Use of an investigational product for which less than 30 days or 5 half-lives have elapsed from the final product administration. Participation in a non-interventional clinical study does not exclude eligibility.

11. Known or suspected history or evidence of a medical condition that, in the investigator's judgment, would expose a participant to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the study

Related Conditions & MeSH terms

• Refractory Status Epilepticus
• Status Epilepticus

Intervention

Drug:
• Ganaxolone
Ganaxolone will be administered as IV solution.
• Placebo
Placebo will be administered as IV solution.
• Standard of care
A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.

Locations

Country	Name	City	State
Austria	Medical University of Innsbruck	Innsbruck
Austria	Kepler Universitätsklinikum GmbH	Linz
Austria	Kepler University Hospital	Linz
Austria	Paracelsus Medical University Salzburg, Christian Doppler University Hospital, Department of Neurology	Salzburg
Austria	Medical University Vienna	Wien
Belgium	Hôpital Universitaire de Bruxelles - Hôpital Erasme	Bruxelles
Belgium	UZA University Hospital Antwerpen	Edegem
Belgium	University Hospitals Leuven	Leuven
Croatia	Dubrava University Hospital	Zagreb
Croatia	University Hospital Centre Zagreb	Zagreb
Czechia	Mazaryk University, Brno,The First Department of Neurology	Brno
Czechia	University Hospital Ostrava	Ostrava
Czechia	Motol University Hospital	Prague
Finland	Helsinki University Hospital	Helsinki
Finland	Kuopio University Hospital	Kuopio
France	Hopital R. Salengro	Lille
France	Hospices Civils de Lyon	Lyon
France	CHRU Nancy	Nancy
France	Chu de Toulouse	Toulouse
Germany	Universitätsklinikum Erlangen	Erlangen
Germany	Epilepsy Center Hessen	Marburg
Germany	University of Osnabruck, Dep of Neurology, Osnabrück	Osnabrück	Osnabruck
Germany	Universität- und Rehabilitationskliniken Ulm, RKU	Ulm
Hungary	National Institute of Clinical Neurosciences	Budapest
Israel	Soroka Medical Center	Be'er Sheva	Beer-Sheva
Israel	Hadassah Medical Center	Jerusalem
Israel	Sheba Medical Center	Tel Aviv
Israel	Tel-Aviv Sourasky Medical Center	Tel aviv
Italy	Azienda Ospedaliero Universitaria Caregg	Firenze
Italy	Università Cattolica del Sacro Cuore	Milan
Italy	Azienda Ospedaliera Universitaria di Modena	Modena
Italy	Azienda Ospedaliera Universitaria Integrata di Verona	Verona
Lithuania	Vilnius University Hospital Santaros Klinikos	Vilnius
Poland	Oddzial Neurologii z Pododdzialem Udarowym Górnoslaskie Centrum Medyczne im. prof. Leszka Gieca Slaskiego Uniwersytetu Medycznego w Katowicach	Katowice	Katowice-Ochojec
Poland	Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Stanislawa Szyszko Slaskiego Uniwersytetu	Katowice
Poland	Uniwersyteckie Centrum Kliniczne im. prof. K. Gibinskiego w Katowicach	Katowice
Poland	Oddzial Kliniczny Neurologii, Szpital Uniwersytecki w Krakowie	Kraków	Krakow
Poland	Samodzielny Publiczny Szpital Kliniczny	Lublin
Poland	WSS im Gromkowskiego	Wroclaw
Slovakia	II. Neurologická klinika SZU Fakultná nemocnica s poliklinikou F. D. Roosevelta Banská Bystrica	Banská Bystrica
Slovakia	SlovakiaNeurologická klinika SZU a UNB Nemocnica Ružinov Univerzitná nemocnica Bratislava	Bratislava
Slovakia	Neurologické oddelenie Nemocnica Agel Levoca a.s.	Levoca
Slovakia	Neurologické oddelenie Fakultná nemocnica	Trnava
Spain	Hospital Santa Creu i Sant Pau, Institut de Recerca Biomedica Sant Pau	Barcelona
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Hospital Clinico San Carlos Madrid.	Madrid
Spain	Hospital Regional Universitario de Málaga	Málaga
Switzerland	Hôpitaux Universitaires de Genève (HUG)	Geneva
Switzerland	Centre Hospitalier Universitaire Vaudois (CHUV)	Lausanne
United Kingdom	Cardiff and Vale UHB	Cardiff
United Kingdom	King's College Hospital, Department of Neurology	London
United Kingdom	Oxford University Hospitals NHS Foundation Trust	Oxford

Sponsors (1)

Lead Sponsor	Collaborator
Marinus Pharmaceuticals

Countries where clinical trial is conducted

Austria,  Belgium,  Croatia,  Czechia,  Finland,  France,  Germany,  Hungary,  Israel,  Italy,  Lithuania,  Poland,  Slovakia,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of participants who will report cessation of SE within 30 minutes of investigational product (IP) initiation of at least 30 minutes duration	Status epilepticus cessation will be determined by the investigator based on clinical and electroencephalography (EEG) features	Up to 30 minutes
Primary	Percentage of participants who will report no escalation of treatment for persistent or recurrent SE within 36 hours of IP initiation		Up to 36 hours
Secondary	Percentage of participants who will report cessation of SE within 30 minutes of IP initiation of at least 30 minutes duration		Up to 30 minutes
Secondary	Percentage of participants who will report no escalation of treatment for persistent or recurrent SE within 72 hours of IP initiation		Up to 72 hours
Secondary	Time to SE cessation		Up to 72 hours
Secondary	Percentage of participants having cessation of SE within 30 minutes of IP initiation of at least 30 minutes duration without escalation of treatment		Up to 30 minutes
Secondary	Percentage of participants reporting no escalation of treatment for persistent or recurrent SE within 36 hours of IP initiation		Up to 36 hours
Secondary	Percentage of participants reporting no escalation of treatment for persistent or recurrent SE within 72 hours of IP initiation		Up to 72 hours
Secondary	Change from Baseline in Modified Rankin Scale (mRS) at the time of hospital discharge	The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death where 0 - No symptoms; 1=No significant disability. Able to carry out all usual activities, despite some symptoms; 2=Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3=Moderate disability. Requires some help, but able to walk unassisted; 4=Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5=Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6=Dead. Higher scores will indicate high degree of disability.	Baseline and Up to Day 31
Secondary	Change from Baseline in level of responsiveness as assessed by the Full Outline of UnResponsiveness (FOUR) Score scale	The FOUR Score is a 17-point scale (with potential scores ranging from 0 - 16). Decreasing FOUR Score is associated with worsening level of consciousness. The FOUR coma scale includes 4 parameters with a minimum score of 0 and a maximum score of "4" for each of them: eye reactions (eye opening and tracking), motor responses (pain response and simple commands), stem reflexes (pupillary, corneal and cough) and respiratory patterns (respiratory rhythm and respiratory attempts in patients on a ventilator). The points are summed up, their sum is estimated. The interpretation of results will be as 15 to 16 score: clear consciousness; Less than 15: Impairment of consciousness; from 4 to 8: Coma and 0-4: Death. Lower the score, the greater the coma gravity.	Baseline and at 24, 36 and 72 hours
Secondary	Change from Baseline in level of sedation/ agitation as assessed by Richmond Agitation and Sedation Scale (RASS)	The RASS is a medical scale used to measure the agitation or sedation level. It is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm. higher scores indicate more agitation.	Baseline and at 24, 36 and 72 hours
Secondary	Percentage of participants with mRS > 3 at the time of hospital discharge	The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death where 0 - No symptoms; 1=No significant disability. Able to carry out all usual activities, despite some symptoms. 2=Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3=Moderate disability. Requires some help, but able to walk unassisted. 4=Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5=Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6=Dead. Higher scores will indicate high degree of disability.	Up to 122 hours
Secondary	Change from Baseline in Clinical Global Impression-Improvement (CGI-I) following IP initiation and at hospital discharge	The CGI-I is a 7-point Likert scale that the parent(s)/caregiver(s)/legally authorized representative (LAR)(s) and clinician uses to rate the change in overall seizure control, behavior, safety, and tolerability after initiation of the IP relative to Baseline (prior to treatment with the IP). It was rated as: 1- "very much improved", 2- "much improved', 3- "minimally improved", 4- "no change", 5- "minimally worse", 6- "much worse", and 7- "very much worse". Higher scores indicated worse condition.	Baseline and at 24, 36, and 72 hours
Secondary	Number of hours on positive pressure ventilation attributable to the episode of SE or its treatment	Healthcare Utilization Questionnaires include the Hospitalization Questionnaire and the Positive Pressure Ventilation (PPV) and Intubation Questionnaire. The Hospitalization Questionnaire should be collected at hospital discharge or at final study visit/contact. The need for non-invasive or invasive ventilatory support within 24 hours prior to IP initiation and following IP initiation and within 48 hours following IP discontinuation should be collected as close as possible to the event.	Up to 4 Weeks
Secondary	Number of hours on positive pressure ventilation		Up to 4 Weeks
Secondary	Length of stay (days) in intensive care unit (ICU)		Up to 4 Weeks
Secondary	Length of stay (days) in hospital		Up to 4 Weeks
Secondary	Percentage of participants requiring artificial ventilation after initiation of IP		Up to 122 hours
Secondary	Percentage of participants not requiring IV anesthesia for SE treatment within 36 hours of IP initiation		Up to 36 hours
Secondary	Percentage of participants not requiring IV anesthesia for SE treatment within 72 hours of IP initiation		Up to 72 hours
Secondary	Percentage of participants not requiring IV anesthesia for SE treatment through the final study follow-up visit/contact		Up to 4 Weeks
Secondary	Percentage of participants who do not develop super refractory status epilepticus (SRSE) through the final study follow-up visit/contact		Up to 4 Weeks
Secondary	Change from Baseline in Euro Quality of Life (five-level EuroQoL five-dimensional [EQ-5D-5L]) score	The EQ-5D-5L is the EuroQoL 5D-5L, a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state. A positive score means quality of life improvement, a negative score, a worsening of quality of life. Higher scores indicate more problems.	Baseline and Up to 4 Weeks
Secondary	Number of AEDs at discharge		Up to 122 hours
Secondary	Percentage of participants requiring supplemental oxygen after initiation of IP		Up to 4 Weeks